Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases

Antonio Cortese, Ramona Lucchetti, Alessio Altobelli, Antonella Conte, Marco Primavera, Guido Valesini, Enrico Millefiorini, Rossana Scrivo

Research output: Contribution to journalArticle

Abstract

The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1κ monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.

Original languageEnglish
Pages (from-to)193-195
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume35
DOIs
Publication statusPublished - Oct 2019

Fingerprint Dive into the research topics of 'Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases'. Together they form a unique fingerprint.

  • Cite this